CYP2C19 and major depressive disorder: Although the association between CYP2C19 polymorphisms and ESC efficacy and safety has been well studied among multiple populations, to our knowledge, this is the first study showing the association between CYP2C19 polymorphisms and ESC long-term treatment responses in Brazilian patients with MDD.